{
    "nctId": "NCT05753657",
    "briefTitle": "A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.",
    "officialTitle": "A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Breast Cancer, Hyperinsulinism, Hyperglycemia Drug Induced",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Rate of severe (grade 3 and 4) hyperglycemia in patients enrolled in the study and in patients treated per protocol",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with ER positive HER2 negative metastatic breast cancer, harboring an activating PIK3CA mutation, scheduled to start treatment with Alpelisib and fulvestrant.\n* Ages 18 - 85\n* ECOG performance status 0, 1 or 2\n* Ability to understand and willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Alpelisib\n* Uncontrolled diabetes mellitus, defined as HbA1c above 8%\n* Diabetes mellitus controlled by insulin\n* Uncontrolled intercurrent illness including, but not limited to: active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnancy\n* Known allergy to pioglitazone",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}